Marker Therapeutics Inc (MRKR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.90-11.34%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · MRKR
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
We anticipate clinical initiation of our study in pancreatic cancer in the first quarter of 2027 and look forward to advancing MT-601 as a potential treatment option for patients with a significant u…
Stated in a supplied disclosure. Management reported: “The study demonstrated a favorable safety profile and disease control rate of 84.6% in patients receiving multi-antigen targeted T cells in combination with frontline chemotherapy, with a median duration of response of 7.5 months and a median overall survival of 14.1 months.” “We anticipate clinical initiation of our study in pancreatic cancer in the first quarter of 2027 and look forward to advancing MT-601 as a potential treatment option for patients with a significant unmet medical need.””
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence.
Stated in a supplied disclosure. Management reported: “To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence.”
The FDA grant award further expands Marker’s track record of securing competitive federal and state research funding to support the development of the Company’s innovative MAR-T cell therapies.
Stated in a supplied disclosure. Management reported: “Today, Marker announced that the Company has been awarded $2.6 million from the U.S. Food and Drug Administration (FDA) through its Orphan Products Clinical Trials grants program.”
Ensure existing cash and equivalents fund operating expenses through the fourth quarter of 2026.
Focus on increasing revenue to improve financial performance.
Over the trailing year it converted 1.02x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, Fed net liquidity, long-term interest rates, the US dollar, real (inflation-adjusted) rates (low R² over the window).
8 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated stable grew net income 43% of the time over the next year (vs 45% for the rest of the cohort, n=9530).
Not investment advice. As of 2026-11-05.